Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: OLD JAKE JUSTUS who wrote (4006)	5/23/1999 7:29:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4891

The nay-sayers have not been around for long time. They must have gotten as tired as us long term holders. It's a lot calmer on one's stomach if you study ADVR technically and it's looking pretty good these days! Relative Strength is at 70% and climbing! Plug in ADVR and do a little TA! askresearch.com ADVR is clearly in an uptrend! clearstation.com Now when ADVR finally pours in a little fundamentals, it can cruise to a higher altitude! Merck and Monsanto recently had their COX-2 inhibitors approved with expected sales to reach $2 billion in the next two years. Not bad for a drug that only relieves the pain of arthritis! Sunday May 23, 2:14 pm Eastern Time Merck Hopes New Pill Will Ease Pain By PHIL GALEWITZ AP Business Writer NEW YORK (AP)-- Merck & Co. made a $5.2 billion profit last year on nearly $27 billion in sales. But the future of the nation's largest drugmaker is uncertain as four of its blockbuster drugs lose patent protection in the next two years, which make them susceptible to competition from cheaper generics. That's why analysts say Merck desperately needs strong sales from its new pain pill Vioxx, which was approved Friday by the Food and Drug Administration and is expected to reach pharmacies in mid-June. Vioxx, though, will have to compete with another new painkiller, Celebrex, which has been the hottest selling drug of the year. Doctors have written 4.4 million prescriptions for Celebrex, jointly marketed by Monsanto and Pfizer, since it was launched in early January. Celebrex this spring became the second fastest selling new drug ever, after the anti-impotence pill Viagra. Vioxx and Celebrex are in a new class of drugs known as COX-2 inhibitors. They offer the same pain relief as traditional arthritis drugs but cause fewer side effects, especially ulcers and intestinal bleeding. Although Merck and Monsanto have touted tests showing fewer side effects on their drugs, the FDA has ordered both to place standard warnings about the potential for stomach problems on their labels. Merck won a slight marketing edge Friday as the FDA approved Vioxx for menstrual pain, acute pain in adults and osteoarthritis. Celebrex is also approved for osteoarthritis, which is the wear and tear of joints usually linked with aging, as well as for rheumatoid arthritis, in which the body's immune system backfires to cause pain and inflammation. Once the FDA approves a drug for one disease, doctors can prescribe it for other ailments. ( does this mean that once RETICULOSE is approved, doctors can prescribe it for other ailments?---no wonder ADVR applied for all those use patents!) As a result, analysts say it is likely doctors will use Vioxx and Celebrex interchangeably. The battle between the drugs will take place in physician offices as thousands of pharmaceutical sales representatives prod doctors to give out free samples. Heavy consumer advertising should also start later this year. Both drugs also will battle to gain acceptance from managed care companies, which increasingly restrict pharmaceutical coverage. Celebrex is covered by about half of all health maintenance organizations. Analysts expect both drugs to each eventually surpass $2 billion in annual sales by 2002. --------------------------------------------------------------- Wonder what RETICULOSE will bring in when it is shown to have positive effects on Rheumatoid Arthritis!